Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
10.92
-0.07 (-0.64%)
At close: Sep 3, 2026, 4:00 PM EDT
10.90
-0.02 (-0.18%)
After-hours: Sep 3, 2026, 5:20 PM EDT
Sagimet Biosciences Employees
Sagimet Biosciences had 16 employees as of December 31, 2025. The number of employees increased by 2 or 14.29% compared to the previous year.
Employees
16
Change (1Y)
2
Growth (1Y)
14.29%
Revenue / Employee
n/a
Profits / Employee
-$2,942,438
Market Cap
678.77M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 16 | 2 | 14.29% | 16 | 0 |
| Dec 31, 2024 | 14 | 4 | 40.00% | 14 | 0 |
| Dec 31, 2023 | 10 | 0 | - | 8 | 2 |
| Dec 31, 2022 | 10 | 3 | 42.86% | 9 | 1 |
| Dec 31, 2020 | 7 | - | - | 6 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Gyre Therapeutics | 625 |
| Valneva SE | 620 |
| CorMedix | 191 |
| Allogene Therapeutics | 152 |
| Prime Medicine | 146 |
| OmniAb | 89 |
| BridgeBio Oncology Therapeutics | 88 |
SGMT News
- 1 day ago - Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences - GlobeNewsWire
- 9 days ago - Sagimet Biosciences advances AURORA clinical trial - TheFly
- 9 days ago - Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026 - GlobeNewsWire
- 17 days ago - Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 17 days ago - Sagimet Biosciences price target raised to $56 from $49 at Canaccord - TheFly
- 18 days ago - Sagimet Biosciences price target raised to $29 from $12 at Citizens - TheFly
- 21 days ago - Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients - GlobeNewsWire
- 23 days ago - Sagimet Biosciences Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts